EcoDrugPlus

Renin-Like

Ensembl ID : ENSCVAG00000011718
Gene Symbol: LOC107090387
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSCVAG00000005428
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSCVAG00000007194
Gene Symbol: LOC107103184
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSCVAG00000014246
Gene Symbol: LOC107101756
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSCVAG00000011770
Gene Symbol: LOC107103632
2 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSCVAG00000012828
Gene Symbol: RARG
3 Cross references
383 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSCVAG00000001661
Gene Symbol: LOC107082109
3 Cross references
367 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSCVAG00000016296
Gene Symbol: RXRA
3 Cross references
231 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSCVAG00000001937
Gene Symbol: LOC107081643
3 Cross references
214 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSCVAG00000011424
Gene Symbol: RPL10
3 Cross references
407 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSCVAG00000005717
Gene Symbol: RPL10A
3 Cross references
380 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSCVAG00000019408
Gene Symbol: RPL11
3 Cross references
287 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).